Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Allotment

 In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors at their meeting held today i.e., Monday, 9th May, 2022 (commenced at 10:30 A.M. and concluded at 11:30 A.M.), inter-alia, approved the allotment of 1,14,65,201, 0.01%, Compulsorily Convertible Preference Shares ('CCPS') of Rs. 100/- each, convertible into 2,13,42,505 Equity Shares of Rs. 2/- each, at an issue price of Rs. 53.72/- per Equity Share, within a maximum period of 18 months in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.
09-05-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, as amended, we wish to inform you that the audio recordings of 'Analyst/ Investor Conference Call' held today, i.e., Friday, 6th May, 2022 at 4.00 P.M. (IST), on post declaration of results for quarter and financial year ended March 31, 2022, is available on the Company''s website.
06-05-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Statement Of Deviation Or Variation In Utilization Of Funds Raised Pursuant To Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there is no Deviation or Variation in utilization of funds raised in the quarter ended March 31, 2022. Please find enclosed Nil Statement of Deviation or Variation in this regard. You are requested to take the note of the same in your record.
05-05-2022

Morepen Lab Consolidated March 2022 Net Sales at Rs 368.28 crore, up 28.5% Y-o-Y

 NULL
05-05-2022
Bigul

Q4FY22 Quarterly Result Announced for Morepen Laboratories Ltd.

 Pharmaceuticals company Morepen Laboratories declares Q4FY22 result: Morepen Labs Annual FY22 Revenue up by 30% with Profit before Tax (PBT) growth of 29% API Export registered a growth of 17%. Annual revenues for FY22 at Rs. 1557.13 crores is up by 30 percent while EBITDA for FY22 at Rs. 146.98 cr. up 13%. Annual FY22 profit before tax (PBT) is up by 29 percent at Rs. 126.70 crore and profit after tax (PAT) at Rs. 101.68 cr. up by 5 percent. Quarterly Revenue (Q4’FY22) grows up to Rs. 371.46 cr. up 28 percent on quarterly basis with a EBIDTA of Rs.21.85 cr. and PBT of Rs.14.18 cr. and PAT of Rs.12.32 cr. Revenue growth for the current year was led by Devices Business, which grew by 46 percent followed by API business which grew by 25 percent. Got USFDA approval of the anti-allergy product Fexofenadine last quarter, for which shipments have started in USA market this quarter. Annual Export Revenues for FY22 at Rs. 557.48 cr. are up by 17 percent YoY basis Formulation and OTC revenues grew up by 28 percent and 24 percent respectively. Promoters holding increased from 34.54 percent to 38.38 percent post conversion of 2.80 crore Warrants out of 7.00 crores warrants allotted last year Got shareholders approval for conversion of Optionally Convertible Preference Shares (OCPS) of Rs. 114.65 crores issued the Banks to Equity shares; regulatory approvals awaited. Mr. Sushil Suri, Chairman and Managing Director stated, “The company has been able to expand its market share and grown in all business segments and expects to increase its profitability parameters in the next few quarters once the supply disruptions are normalized, which have resulted in increased input costs. The company continues to invest in developing new markets and launch new products to reach to more and more customers”. Mr. Suri further added, “We have got shareholder’s approval for the conversion of Bank’s Preference shares into equity capital, which is underway, while we wait for the regulatory approvals. It will be a big milestone for the company, once the process is completed” Result PDF
05-05-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed press release on the financial performance of the Company for the quarter and financial year ended 31st March 2022 with the title - 'Morepen Labs Annual FY22 Revenue up by 30% with Profit before Tax (PBT) growth of 29 %, API Export registered growth of 17%'.
05-05-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find enclosed the Investors Presentation (Q4'FY22) May, 2022, based on the financial performance of the Company for the quarter and financial year ended 31st March, 2022.
05-05-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Results For The Q4 FY 2022

 Results for the Q4 FY 2022
05-05-2022
Bigul

Annual report for Morepen Laboratories Ltd. for FY-2022
05-05-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of Audited Financial Results for the quarter and financial year ended 31st March, 2022, the Company is organizing an 'Analyst/ Investor Conference Call' on Friday, 6th May, 2022 at 4.00 P.M. (IST). The details of the conference call are attached herewith.
04-05-2022
Next Page
Close

Let's Open Free Demat Account